FT News Briefing The year of weight-loss drugs
Dec 22, 2023
The discussion explores the potential for the Bank of England to lower interest rates in 2024 amid economic improvements. It dives into how innovative weight-loss drugs like Ozempic and Wegovi are reshaping healthcare and societal views on obesity. Celebrity culture exploits these medications, raising concerns about accessibility for those in need. Additionally, the podcast highlights India's booming fertility industry, revealing personal stories and the challenges couples face in conception amidst increasing investment in private clinics.
AI Snips
Chapters
Transcript
Episode notes
FT Person of the Year
- Novo Nordisk CEO, Lars Fruergaard Jørgensen, is the FT's Person of the Year.
- His company's obesity drugs, Ozempic and Wegovy, are changing healthcare.
Preventative Potential of Weight-Loss Drugs
- Ozempic and Wegovy are not just slimming drugs.
- They are powerful preventative tools, reducing serious cardiac event risks.
Ozempic in Hollywood
- Kim Kardashian's Met Gala appearance fueled Ozempic's popularity.
- The drugs became a cultural phenomenon, even a joke at the Oscars.